;
Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: VC tracks

    Canaan Partners promoted Tim Shannon to general partner and Julie Papanek to principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp. through its sale to Celldex …

    Published on 10/17/2014
  • COMPANY NEWS: Aduro, J&J in second cancer pact

    Immunotherapy specialist Aduro BioTech Inc. (Berkeley, Calif.) entered into its second licensing agreement with the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE: JNJ). The biotech granted Janssen …

    Published on 10/16/2014
  • COMPANY NEWS: FDA reviewers back Novartis' psoriasis mAb

    FDA reviewers said "available data support a favorable benefit-risk assessment" for Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) to treat moderate to severe plaque psoriasis in adults who are candidates …

    Published on 10/16/2014
  • COMPANY NEWS: Immune Design boosted by compound pooling deal with Sanofi

    Immune Design Corp. (NASDAQ:IMDZ) added $2.22 (11%) to $23.23 on Thursday after it announced a deal with Sanofi (Euronext:SAN; NYSE:SNY) to pool compounds in a discovery and development deal focused on immune therapies…

    Published on 10/16/2014
  • COMPANY NEWS: Regeneron Genetics Center adds 3 academic deals

    The Regeneron Genetics Center LLC (RGC) of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) expanded its footprint with three new partnerships with academic research centers and the formation a scientific advisory board. …

    Published on 10/16/2014
  • COMPANY NEWS: Shire stabilizes as investors look past AbbVie

    Shares of Shire plc plc (LSE:SHP; NASDAQ:SHPG) added $7.97 to $178.46 on NASDAQ on Thursday as investors mulled the company's prospects after the board of AbbVie Inc. (NYSE:ABBV) recommended that stockholders vote …

    Published on 10/16/2014
  • COMPANY NEWS: AbbVie reconsidering Shire acquisition

    Shire plc (LSE:SHP; NASDAQ:SHPG) plunged $74.08 (30%) to $170.49 on NASDAQ on Wednesday after AbbVie Inc. (NYSE:ABBV) said it will reconsider the companies' planned merger. Shire is off $22 (11%) from its June 19 close…

    Published on 10/15/2014
  • COMPANY NEWS: Chimerix gives update on brincidofovir, CMX16669

    Chimerix Inc. (NASDAQ:CMRX) announced next steps for development of brincidofovir to treat Ebola and other viral infections in an R&D update. The company also plans to file an IND for CMX16669 to treat cytomegalovirus (…

    Published on 10/15/2014
  • COMPANY NEWS: Orexigen ships Contrave; head-on pricing set

    Orexigen Therapeutics Inc. (NASDAQ:OREX) said it received a $70 million milestone payment from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) after it sent the first shipment of obesity drug Contrave naltrexone/bupropion…

    Published on 10/15/2014
  • COMPANY NEWS: J&J offers Olysio cost-sharing in Scotland

    The Scottish Medicines Consortium recommended Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ) in combination with other therapies to treat chronic HCV genotypes 1 and 4 infection in …

    Published on 10/14/2014
  • COMPANY NEWS: NICE spurns Celgene's Imnovid for MM

    The U.K.'s NICE issued draft guidance recommending against use of Imnovid pomalidomide from Celgene Corp. (NASDAQ:CELG) in combination with dexamethasone to treat relapsed and refractory multiple myeloma (MM). The …

    Published on 10/14/2014
  • COMPANY NEWS: Priority Reviews for Eisai's lenvatinib and rufinamide

    Eisai Co. Ltd. (Tokyo:4523) said FDA accepted for filing and granted Priority Review to an NDA for lenvatinib (E7080) and an sNDA for rufinamide (E2080). Eisai is seeking approval of lenvatinib to treat progressive, …

    Published on 10/14/2014
  • COMPANY NEWS: BMS, Pharmacyclics to test Opdivo/Imbruvica combo

    Bristol-Myers Squibb Co. (NYSE:BMY) partnered with Pharmacyclics Inc. (NASDAQ:PCYC) and Johnson & Johnson (NYSE:JNJ) to evaluate BMS's Opdivo nivolumab in combination with Imbruvica ibrutinib in a Phase I/II trial to…

    Published on 10/13/2014
  • COMPANY NEWS: Priority Review for Pfizer's palbociclib

    Pfizer Inc. (NYSE:PFE) said FDA accepted for filing and granted Priority Review to an NDA for palbociclib in combination with Femara letrozole as first-line treatment for postmenopausal women with estrogen receptor-…

    Published on 10/13/2014
  • COMPANY NEWS: Exact up on Cologuard reimbursement

    Exact Sciences Corp. (NASDAQ:EXAS) jumped $6.48 (36%) to $24.60 on Friday, adding $537.4 million in market cap to $2 billion, on news CMS has proposed reimbursement of $502 for Cologuard, the company's non-invasive DNA…

    Published on 10/10/2014
  • COMPANY NEWS: FDA approves Helsinn's Akynzeo combo for CINV

    FDA approved Akynzeo netupitant/palonosetron from Helsinn Healthcare S.A. (Lugano, Switzerland) to treat chemotherapy-induced nausea and vomiting (CINV).Akynzeo, previously known as NEPA, is a fixed-dose combination of …

    Published on 10/10/2014
  • COMPANY NEWS: Management tracks

    Roth Capital Partners named John Chambers vice-chairman. Chambers, who joined ROTH in 2009, remains head of its healthcare investment banking group. He was previously the head of the healthcare and investment banking …

    Published on 10/10/2014
  • COMPANY NEWS: Alexion names CEO Bell chairman

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) named CEO Leonard Bell as its chairman, three days after the passing of former chairman Max Link (see BioCentury Extra, Oct. 8).Bell, a principal founder of Alexion, remains …

    Published on 10/9/2014
  • COMPANY NEWS: Auxilium accepts Endo's richer buyout bid

    Endo International plc (NASDAQ:ENDP; TSX:ENL) won its bid to acquire Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), striking a deal they valued at $33.25 per share in stock and cash, or $2.6 billion. Auxilium agreed to …

    Published on 10/9/2014
  • COMPANY NEWS: CMS confirms national coverage for Cologuard

    CMS finalized its National Coverage Determination for the Cologuard non-invasive DNA screening test for colorectal cancer from Exact Sciences Corp. (NASDAQ:EXAS), the first product that has undergone a pilot parallel …

    Published on 10/9/2014
  • COMPANY NEWS: FDA approves Velcade for first-line MCL

    FDA approved an sNDA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to expand the label of Velcade bortezomib to include first-line mantle cell lymphoma (MCL). The pharma said Velcade is the first treatment to be …

    Published on 10/9/2014
  • COMPANY NEWS: FDA wants pediatric ADHD data from Shire

    FDA requested additional pediatric data from Shire plc (LSE:SHP; NASDAQ:SHPG) to support resubmission of an NDA for SHP465 triple-bead mixed amphetamine salts (MAS) to treat ADHD in adults.Prior to FDA's request, Shire…

    Published on 10/9/2014
  • COMPANY NEWS: Priority Review for Amgen's blinatumomab BiTE

    FDA accepted and granted Priority Review to a BLA for blinatumomab (AMG 103) from Amgen Inc. (NASDAQ:AMGN) to treat adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (…

    Published on 10/9/2014
  • COMPANY NEWS: "Surprised" Arrowhead responds

    Shares of Arrowhead Research Corp. (NASDAQ:ARWR) were off $0.11 to $6.92 on Thursday after the company issued an "open letter" in which it said it was taken "by surprise" by shareholder reaction to publication of an …

    Published on 10/9/2014
  • COMPANY NEWS: Vertex gives update in CF

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) updated the progress of multiple programs as it prepared to present data at the North American Cystic Fibrosis Conference beginning today in Atlanta. The company said it has …

    Published on 10/9/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993